EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells

Weiran Shan, Kendrick Zuo, Zhiyi Zuo iD

Journal of Cellular and Molecular Medicine · 2024

DOI: 10.1111/jcmm.70260 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Weiran Shan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Glioblastoma, Cell Movement, Cell Proliferation, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Virginia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme is a deadly brain tumour in humans. We have shown that regulatory factor X1 (RFX1), a transcription factor, inhibits the proliferation, migration and invasion of human glioblastoma cells. This study was designed to identify the existing medications that could increase RFX1 in human glioblastoma cells and to determine whether these medications could inhibit the cancer cell behaviours. A bioinformatics approach was used to identify the medications that increased RFX1. The effects of these medications on human glioblastoma cell proliferation, migration and invasion were assayed under cell culture and mouse brain xenograft conditions. Pioglitazone, rosiglitazone and WY‐14643 increased RFX1 based on bioinformatics prediction and Western blotting data. These hypoglycemic agents reduced the proliferation, migration and invasion of human glioblastoma cell cultures. These agents reduced metalloproteinase 2 (MMP2) activity in the culture medium. Silencing RFX1 attenuated hypoglycemic agent‐induced inhibition of cancer cell behaviours and MMP2 activity. Pioglitazone reduced the xenograft tumour volume and migration distance of U87 human glioblastoma cells in the mouse brain. RFX1‐siRNA attenuated these effects. Our results provide additional evidence for RFX1 as a therapeutic target for human glioblastoma and suggest that pioglitazone, rosiglitazone and WY‐14643 inhibit cancer cell behaviour of human glioblastoma cells via upregulating RFX1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaCell MovementCell ProliferationHypoglycemic AgentsRegulatory Factor X1HumansAnimalsCell Line, TumorMiceRosiglitazoneXenograft Model Antitumor AssaysMatrix Metalloproteinase 2PioglitazoneBrain NeoplasmsGene Expression Regulation, NeoplasticPyrimidinesMice, NudeNeoplasm Invasiveness

Stichwörter der Autor:innen

WY‐14643human glioblastoma cellsmetalloproteinase 2regulatory factor X1thiazolidinediones

Substanzen

Hypoglycemic AgentsRegulatory Factor X1RosiglitazoneMatrix Metalloproteinase 2RFX1 protein, humanPioglitazonePyrimidines

Autor:innen und Institutionen

  • Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.
  • Kenneth P. Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Zhiyi Zuo

Förderung

  • University of Virginia

Zitieren

APA

Shan, W., Zuo, K., & Zuo, Z. (2024). Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70260

Vancouver

Shan W, Zuo K, Zuo Z. Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70260

BibTeX
@article{Shan2024,
  author = {Shan, Weiran and Zuo, Kendrick and Zuo, Zhiyi},
  title = {Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2024},
  doi = {10.1111/jcmm.70260}
}
Kostenlos starten →